Suzhou Sanegene Bio Inc.’s clinical trial application for SGB-3908 injection, an siRNA drug for the treatment of hypertension, has been accepted in China by the National Medical Products Administration (NMPA)’s Center for Drug Evaluation (CDE).
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).
Japanese researchers have transplanted human induced pluripotent stem cells (iPSCs) in a primate model of myocardial infarction and were able to restore heart muscle and function in monkeys. Developed by Tokyo-based Heartseed Inc., the grafted iPSCs consist of clusters of purified heart muscle cells (cardiomyocyte spheroids) that are injected into the myocardial layer of the heart. Published in Circulation on April 26, 2024, the study showed that the cardiomyocyte spheroids survived long term and showed improved contractile function with low occurrence of post-transplant arrhythmias.
Scientists at Massachusetts General Hospital have linked the risk of heart failure during pregnancy and senescence proteins produced by placental aging, which could clarify how peripartum cardiomyopathy (PPCM) is triggered and opens the door to the development of cardiac function therapies in late pregnancy.
New York University has disclosed RAGE receptor antagonists reported to be useful for the treatment of cancer, SARS-CoV-2 infection (COVID-19), diabetic complications, ischemia reperfusion injury, neurodegeneration, obesity, and cardiovascular and inflammatory disorders, among others.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed compounds reported to be useful for the treatment of arterial aneurysm.
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby increasing LDL cholesterol levels. PCSK9 inhibition has emerged as a promising strategy for cardiovascular diseases. However, it is still unclear whether PCSK9 can trigger blood vessel inflammation directly modulating monocytes or endothelial cells independently of LDL receptor.
Researchers from Hefei Industrial Pharmaceutical Institute Co. Ltd. published data detailing the design and biological evaluation of novel NMDAR-GluN2B antagonists as potential candidates for the treatment of ischemic stroke.
Cereno Scientific AB has submitted a clinical trial application (CTA) to the EMA seeking approval for a first-in-human, phase I study of CS-014, a novel histone deacetylase (HDAC) inhibitor drug candidate under development as an antithrombotic treatment.
Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis is a systemic condition affecting the small vessels with production of MPO-ANCA in serum. It has been suggested that the formation of neutrophil extracellular traps (NETs) induced by MPO-ANCA is a driver of pathogenesis, with involvement of neutrophil elastase (NE), which in turn is activated by the enzyme cathepsin C.
RSS
